Login / Signup

Preclinical characterization of 55P0251, a novel compound that amplifies glucose-stimulated insulin secretion and counteracts hyperglycaemia in rodents.

Karin StadlbauerBarbara BrunmairZsuzsanna LehnerImmanuel AdorjanThomas SchererAnton LugerLeonhardt BauerClemens Fürnsinn
Published in: Diabetes, obesity & metabolism (2017)
55P0251 is a novel compound that potently counteracts hyperglycaemia in rodents via amplification of glucose-stimulated insulin release.
Keyphrases
  • blood glucose
  • type diabetes
  • glycemic control
  • nucleic acid
  • cell therapy
  • bone marrow
  • metabolic syndrome
  • skeletal muscle
  • mesenchymal stem cells